NuCana (NCNA) Competitors $0.06 0.00 (-1.00%) Closing price 04:00 PM EasternExtended Trading$0.06 +0.00 (+1.01%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NCNA vs. CWBR, EVFM, NMTR, ATXI, PTPI, TRVN, HEPA, PBLA, SYRS, and SRNEShould you be buying NuCana stock or one of its competitors? The main competitors of NuCana include CohBar (CWBR), Evofem Biosciences (EVFM), 9 Meters Biopharma (NMTR), Avenue Therapeutics (ATXI), Petros Pharmaceuticals (PTPI), Trevena (TRVN), Hepion Pharmaceuticals (HEPA), Panbela Therapeutics (PBLA), Syros Pharmaceuticals (SYRS), and Sorrento Therapeutics (SRNE). These companies are all part of the "pharmaceutical products" industry. NuCana vs. Its Competitors CohBar Evofem Biosciences 9 Meters Biopharma Avenue Therapeutics Petros Pharmaceuticals Trevena Hepion Pharmaceuticals Panbela Therapeutics Syros Pharmaceuticals Sorrento Therapeutics NuCana (NASDAQ:NCNA) and CohBar (NASDAQ:CWBR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership. Do analysts recommend NCNA or CWBR? NuCana presently has a consensus price target of $25.00, suggesting a potential upside of 41,776.05%. Given NuCana's stronger consensus rating and higher possible upside, analysts plainly believe NuCana is more favorable than CohBar.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuCana 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50CohBar 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is NCNA or CWBR more profitable? CohBar's return on equity of 0.00% beat NuCana's return on equity.Company Net Margins Return on Equity Return on Assets NuCanaN/A -319.85% -88.55% CohBar N/A N/A N/A Do insiders and institutionals hold more shares of NCNA or CWBR? 44.0% of NuCana shares are owned by institutional investors. Comparatively, 2.5% of CohBar shares are owned by institutional investors. 31.2% of NuCana shares are owned by company insiders. Comparatively, 6.5% of CohBar shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media refer more to NCNA or CWBR? In the previous week, NuCana's average media sentiment score of 0.00 equaled CohBar'saverage media sentiment score. Company Overall Sentiment NuCana Neutral CohBar Neutral Which has higher earnings & valuation, NCNA or CWBR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuCanaN/AN/A-$24.28M-$7.02-0.01CohBarN/AN/A-$12.18MN/AN/A Which has more risk and volatility, NCNA or CWBR? NuCana has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500. Comparatively, CohBar has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500. SummaryNuCana beats CohBar on 6 of the 9 factors compared between the two stocks. Get NuCana News Delivered to You Automatically Sign up to receive the latest news and ratings for NCNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NCNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NCNA vs. The Competition Export to ExcelMetricNuCanaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$363K$2.96B$5.57B$9.02BDividend YieldN/A2.44%5.25%4.03%P/E Ratio-0.0121.1627.2120.15Price / SalesN/A260.59416.26185.35Price / CashN/A41.8337.0657.97Price / Book0.047.768.085.60Net Income-$24.28M-$54.96M$3.16B$248.50M7 Day PerformanceN/A5.99%3.74%5.11%1 Month PerformanceN/A4.41%3.88%7.58%1 Year PerformanceN/A6.36%34.26%21.53% NuCana Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NCNANuCana2.5237 of 5 stars$0.06-1.0%$25.00+41,776.0%-98.0%$363KN/A-0.0130Gap UpHigh Trading VolumeCWBRCohBarN/A$0.41flatN/AN/A$1.19MN/A0.0010EVFMEvofem Biosciences0.6059 of 5 stars$0.01-1.0%N/A-6.5%$1.18M$11.39M-0.02120Gap UpNMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A-0.0220ATXIAvenue Therapeutics2.1667 of 5 stars$0.32-6.2%N/A-93.0%$1.02MN/A0.024Trending NewsPTPIPetros Pharmaceuticals0.6597 of 5 stars$0.03-8.9%N/A-99.7%$991K$5.11M-0.0120Gap DownTRVNTrevena2.4599 of 5 stars$0.91-3.2%$5.00+449.5%-82.0%$873K$443K-0.0240Gap DownHEPAHepion Pharmaceuticals0.3214 of 5 stars$0.07+6.7%N/A-99.9%$787KN/A-0.0220Gap DownPBLAPanbela Therapeutics0.0956 of 5 stars$0.16-1.5%N/A-57.0%$765KN/A0.006Gap UpSYRSSyros Pharmaceuticals4.3542 of 5 stars$0.03+11.6%$3.33+11,804.8%-100.0%$751K$386K-0.01120Gap DownSRNESorrento Therapeutics0.7075 of 5 stars$0.00-7.1%N/A-88.8%$717K$60.32M0.00800 Related Companies and Tools Related Companies CohBar Competitors Evofem Biosciences Competitors 9 Meters Biopharma Competitors Avenue Therapeutics Competitors Petros Pharmaceuticals Competitors Trevena Competitors Hepion Pharmaceuticals Competitors Panbela Therapeutics Competitors Syros Pharmaceuticals Competitors Sorrento Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NCNA) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tie...InvestorPlace | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NuCana PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share NuCana With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
